Special Report: multiple molecular testing of cancers to identify targeted therapies
BlueCross BlueShield Association

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
The objective of this Special Report is to review important concepts underlying the use of multiple molecular testing to guide cancer treatment. Issues and problems underlying the assessment of efficacy of such strategies will be discussed. Published studies that use multiple molecular testing methods to select targeted therapies and that report patient outcomes will be presented.

Authors' conclusions
Use of multiple molecular testing to assist in making treatment decisions for cancer patients is rapidly evolving. Strong evidence of clinical effectiveness of this approach is not available, and a number of issues remain to be solved, particularly patient selection. Different approaches may be taken to the interpretation of multiple molecular marker panels. Clinical trials to determine the effectiveness of this approach will be challenging to complete.

Final publication URL

PubMedID
23865106

Additional data URL

Indexing Status
Subject indexing assigned by NLM

MeSH
Biomarkers, Tumor /genetics; Blue Cross Blue Shield Insurance Plans; DNA Mutational Analysis; Genetic Testings; Molecular Targeted Therapy /methods; Mutation /genetics; Neoplasms /diagnosis /genetics /therapy; Technology Assessment, Biomedical; United States; United States Food and Drug Administration

Language Published
English

Country of organisation
United States

English summary
An English language summary is available.

Address for correspondence
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321 Email: tec@bcbsa.com
AccessionNumber
32013000680

Date abstract record published
23/09/2013